Regulatory Frameworks and Supply Dynamics: In December 2025, the FDA approved the first oral GLP-1 for weight loss-Novo Nordisk's once-daily semaglutide pill, which launched in January 2026, significantly expanding accessibility for patients averse to injections [3]
May need higher doses
Tp luyn cc bi tp tim mch (cardio) Theo khuyn ngh t i hc Y hc Th thao Hoa K (ACSM), cc hot ng cng va phi nh i b nhanh, p xe chm, bi li nh v lm vn gip qun l cn nng hiu qu
At 68 weeks, researchers found that participants taking semaglutide experienced a mean decline in their body weight by 13.7%, compared to a 3.2% decrease in those taking the placebo
focus on walking, light mobility, and easier sets
Trimi $99/mo compounded GLP-1 ranked among the options